Literature DB >> 8762855

Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam.

E Johansson1, V K Diwan, N D Huong, B M Ahlberg.   

Abstract

SETTING: The study, a collaboration between the National Tuberculosis Institute, Hanoi, Vietnam and the Karolinska Institutet, Stockholm, Sweden, was carried out in a district of Quang Ninh Province in North Vietnam.
OBJECTIVES: To describe tuberculosis (TB) services, attitudes of staff, and attitudes of patients considered as defaulters to TB treatment.
DESIGN: Two focus group discussions were carried out with staff at the district hospital. Ten defaulter patients were interviewed in their homes. RESULTS AND
CONCLUSIONS: This exploratory study has revealed some important aspects of staff and patients' attitudes to TB and its treatment. Tuberculosis is considered a 'dirty' disease, which mainly affects poor people. There is a tendency to avoid telling others about it. Obvious symptoms are explained as 'being overworked'. A patient with TB feels 'less respected' by others. The social stigmatization leads to delays in seeking medical care, often only after self-medication: anti-tuberculosis drugs can be bought without prescription in various pharmacies. The patient's economic situation is also an important determinant of compliance and non-compliance. These factors need to be taken into consideration in TB control in Vietnam.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762855     DOI: 10.1016/s0962-8479(96)90035-0

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  18 in total

1.  Patient views on determinants of compliance with tuberculosis treatment in the eastern cape, South Africa: an application of q-methodology.

Authors:  Jane Murray Cramm; Job van Exel; Valerie Møller; Harry Finkenflügel
Journal:  Patient       Date:  2010-09-01       Impact factor: 3.883

Review 2.  Tuberculosis and stigmatization: pathways and interventions.

Authors:  Andrew Courtwright; Abigail Norris Turner
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

3.  The effect of tuberculosis and tuberculosis contact tracing on school function: an exploratory focus group study.

Authors:  R E Upshur; L Deadman; P Howorth; L Shortt
Journal:  Can J Public Health       Date:  1999 Nov-Dec

Review 4.  Quality of life in tuberculosis: a review of the English language literature.

Authors:  Betty Chang; Albert W Wu; Nadia N Hansel; Gregory B Diette
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

5.  Factors associated with low cure rate of tuberculosis in remote poor areas of Shaanxi Province, China: a case control study.

Authors:  Xianqin Ai; Ke Men; Liujia Guo; Tianhua Zhang; Yan Zhao; Xiaolu Sun; Hongwei Zhang; Guangxue He; Marieke J van der Werf; Susan van den Hof
Journal:  BMC Public Health       Date:  2010-03-07       Impact factor: 3.295

6.  Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Authors:  J V Brooks; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Health-related quality of life: A neglected aspect of pulmonary tuberculosis.

Authors:  Ashutosh N Aggarwal
Journal:  Lung India       Date:  2010-01

8.  Quality of life in tuberculosis: patient and provider perspectives.

Authors:  Nadia N Hansel; Albert W Wu; Betty Chang; Gregory B Diette
Journal:  Qual Life Res       Date:  2004-04       Impact factor: 4.147

9.  Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.

Authors:  Argiro Pachi; Dionisios Bratis; Georgios Moussas; Athanasios Tselebis
Journal:  Tuberc Res Treat       Date:  2013-04-15

10.  Community's knowledge, attitudes and practices about tuberculosis in Itang Special District, Gambella Region, South Western Ethiopia.

Authors:  Jango Bati; Mengistu Legesse; Girmay Medhin
Journal:  BMC Public Health       Date:  2013-08-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.